Role of interleukin 6 and alpha-globulins in differentiating Alzheimer and vascular dementias

Neurodegenerative Diseases

Volumn 9, Issue 2, 2012, Pages 81-86

  Helmy, Azza A ^a   Abdel Naseer, Maged M ^a   El Shafie, Shahira ^b   Nada, Mona A F ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b Fayoum University   (Egypt)

Author keywords

Alpha 1 globulins; Alpha 2 globulins; Alzheimer's dementia; Inflammatory markers; Interleukin 6; Serum protein electrophoresis; Vascular dementia

Indexed keywords

ALPHA 2 GLOBULIN; ALPHA GLOBULIN; C REACTIVE PROTEIN; INTERLEUKIN 6;

ADULT; AGED; AGING; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; LABORATORY TEST; MALE; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN ELECTROPHORESIS; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; ALPHA-GLOBULINS; ALZHEIMER DISEASE; AREA UNDER CURVE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DEMENTIA, VASCULAR; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; MALE; MIDDLE AGED; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84856754551     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000329568     Document Type: Article

References (34)

1. Mark RJ, Griffiths WS: Interleukin-1, neuroinflammation, and Alzheimer disease. Neurobiol Aging 2001; 22: 903-908.
2. McGree EG, McGree PL: The importance of inflammatory mechanisms in Alzheimer disease. Exp Gerontol 1998; 33: 371-378.
3. Yaffe K, Lidquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, Launer L, Kuller L, Rubin S, Harris T: Inflammatory markers and cognition in well functioning African-American and White elders. Neurology 2003; 61: 76-80. (Pubitemid 36818750)
4. Folstein MF, Folstein SE, McHugh PR: 'Mini-Mental State': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
5. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994, pp 138-142.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
7. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, Orgogozo JM, Brun A, Hofman A, et al: Vascular dementia: diagnostic criteria for research studies: report of the NINDSAIREN International Workshop. Neurology 1993; 43: 250-260. (Pubitemid 23060253)
8. Hachinski VC, Iliff LD, Zilhka E, Du Boulay GH, McAllister VL, Marshall J, Russell RW, Symon L: Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-637.
9. Petrie A, Sabin C: Medical Statistics at a Glance, ed 2. New York, Blackwell, 2005.
10. Ott A, Breteler MMB, Harskamb F, Claus JJ, van der Cammen TJM, Grobbee DE, Hofman A: Prevalence of Alzheimer disease and vascular dementia: association with education. The Rotterdam Study. BMJ 1995; 310: 970-973.
11. Blasko I, Grubeck-Loebenstein B: Role of immune system in the pathogenesis, prevention and treatment of Alzheimer disease. Drug Aging 2003; 20: 101-113. (Pubitemid 36246292)
12. Hebert R, Lindsay T, Verreault R, Rockwood K, Hill G, Dubois MF: Vascular dementia: incidence and risk factors in the Canadian Study of Health and Aging. Stroke 2000; 31: 1487-1493. (Pubitemid 30437492)
13. Desmond DW, Moroney JJ, Paik MC, Sano M, Mohr JP, Aboumatar S, et al: Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000; 54: 1124-1128.
14. Goldstein FC, Ashley AV, Freedman L, Penix L, Lah LL, Hanfelt J, Levey AI: Hypertension and cognitive performance in African Americans with Alzheimer disease. Neurology 2005; 64: 899-901. (Pubitemid 40316335)
15. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, et al: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002; 346: 476-483. (Pubitemid 34441738)
16. Aliev G, Smith MA, Seyidov D, Neal ML, Lamb BT, Nunomura A, et al: The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol 2003; 12: 21-35.
17. Hansson GK: Inflammation, atherosclerosis and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
18. Peila R, Launer LJ: Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu Asia Aging Study. Diabetes 2006; 51: 1256-1262. (Pubitemid 34438377)
19. De Luigi A, Fragiacomo C, Lucca U, Quadri P, Tettamanti M, Grazia De Simoni M: Inflammatory markers in Alzheimer disease and multi-infarct dementia. Mech Aging Dev 2001; 122: 1985-1995. (Pubitemid 32925108)
20. Sun Y, Minthon L, Wallmark A, Warkentin S, Blennow K, Janciauskiene S: Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer disease. Dement Geriatr Cogn Disord 2003; 16: 136-144. (Pubitemid 36736999)
21. Luchsinger JA, Tang MX, Shea S, Miller J, Green R, Mayeux R: Plasma homocysteine levels and risk of Alzheimer disease. Neurology 2004; 62: 1972-1976. (Pubitemid 38738206)
22. Ravalgia G, Forti P, Maioli F, Chiappellib M, Montesia F, Tuminib E, et al: Blood inflammatory markers and risk of dementia. Neurobiol Aging 2006; 107: 6632-6643.
23. Stewart R, Masaki K, Xue Q-L, Peila R, Petrovitch H, White LR, Launer LJ: A 32-years prospective study of change in body weight and incident dementia: the Honolulu-Asia Aging Study. Arch Neurol 2005; 62: 55-60. (Pubitemid 40105036)
24. Visser M, Pahor M, Taafe DR, Goodpaster BH, Simonsick EM, Newman AB, et al: Relationship of interleukin-6 and tumor necrosis factor alpha with muscle mass and muscle strength in elderly men and women: The Health ABC Study. J Gerontol Med Sci 2002; 57:M326-M332. (Pubitemid 34464974)
25. Cesari M, Penninx BW, Newman AB, Kritchevsky SB, Nicklas BJ, Sutton-Tyrrell K, et al: Inflammatory markers and onset of cerebrovascular events: result from the Health ABC Study. Circulation 2003; 108: 2317-2322. (Pubitemid 37413536)
26. Cacquevel M, Lebeurrier N, Cheenne S, Vivien D: Cytokines in neuroinflammation and Alzheimer disease. Current Drug Targets 2004; 5: 529-534.
27. Schmidt R, Schmidt H, Curb JD, et al: Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002; 52: 168-174. (Pubitemid 34810596)
28. Ravalgia G, Forti P, Maioli F, et al: Blood inflammatory markers and risk of dementia. Neurobiol Aging 2006; 107: 6632-6643.
29. Vesna J, Robert S, Emma D, et al: Markers of inflammation and cognitive decline in an African-Caribbean population. Int J Geriatr Psychiatry 2007; 22: 966-973.
30. Zuliana G, Guerra G, Ranzini M, Rossi L, Munari MR, Zurlo A, et al: High interleukin-plasma levels are associated with functional impairment in older patients with vascular dementia. Int J Geriatr Psychiatry 2007; 22: 305-311. (Pubitemid 46680841)
31. Morely JE, Baumgartner RN: Cytokine-related aging process. J Gerontol A Biol Sci Med Sci 2004; 59:M924-M929.
32. Ershler WB, Keller ET: Age-associated increased interleukin-6 gene expression, late life diseases, and frailty. Ann Rev Med 2000; 51: 245-270. (Pubitemid 30216036)
33. Elwan O, Madkour O, Elwan F, Mostafa M, Helmy A, Abdel-Naseer M, et al: Brain aging in normal Egyptians: cognition, education, personality, genetic and immunological study. J Neurol Sci 2003; 211: 15-22. (Pubitemid 36593262)
34. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, et al: Proteomebased plasma biomarker for Alzheimer disease. Brain 2006; 129: 3042-3050. (Pubitemid 44684524)